Biomed Union Raises RMB 200M in Series B Round for Diagnostic Products
Biomed Union (formerly known as Shanghai Biomed-union Biotechnology Co., Ltd), a tumor molecular diagnostic technology...
November 2022
Yaguo Technology Secures Series A+ Funding for Airway Management Devices
Yaguo Technology Co., Ltd, an airway management and respiratory therapy device maker based in Beijing,...
Novatim Immune Therapeutics Raises RMB 500M in First Financing Round
China-based tumor immunotherapy developer Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has reportedly raised close to...
Pulnovo Medical Raises ‘Tens of Millions’ in New Financing Round
Pulnovo Medical, a pulmonary hypertension (PH) medical device maker based in Wuxi, has reportedly raised...
Akeso Biopharma Completes Enrollment for AK112 Phase III Study
China-based Akeso Biopharma (HKG: 9926) has announced the completion of enrollment for its Phase III...
Eccogene Gains FDA Approval for Phase I Study of ECC5004
Shanghai-based Eccogene has announced receiving approval from the US FDA to initiate a Phase I...
BeiGene’s Brukinsa Receives EU Marketing Approval for Marginal Zone Lymphoma
China-based biotech BeiGene Inc. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced receiving marketing approval from...
Dartsbio Licenses Potential First-in-Class BsAb DS005 to Duality Biologics
China-based Dartsbio Pharmaceuticals, Ltd has announced a licensing deal with Duality Biologics, a novel modality...
Fosun Pharma Terminates Equity Transfer Deal with OncoCare Medical
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the termination of...
Antengene’s CD73 Inhibitor ATG-037 Greenlit for Phase I Study by NMPA
China-based Antengene Corporation Limited (HKG: 6996) has announced receiving approval from the National Medical Products...
Sino Medical Sciences’ Non-Compliant Balloon Catheter Approved by NMPA
China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving market approval from the...
Hengrui’s Pyrotinib Granted Breakthrough Therapy Designation by CDE
The Center for Drug Evaluation (CDE) website indicates that China-based Hengrui Medicine Co., Ltd’s (SHA:...
NMPA Approves Humanwell’s Generic Clobazam for Lennox-Gastaut Syndrome
China-based Yichang Humanwell Pharmaceutical Co., Ltd’s generic version (oral suspension) of Sanofi’s clobazam (trade name:...
NMPA Approves Luye Pharma’s LY03005 for Depression Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that its Category 1 chemical drug LY03005...
Shanghai SMPA Suspends HEC’s Linagliptin Procurement Over Patent Infringement
The Shanghai Sunshine Medical Procurement All-in-One (SMPA) platform has revealed that it has suspended the...
Shanghai Pharmaceuticals Gets NMPA Clearance for Sublingual Rasagiline
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has announced receiving clinical clearance from the National Medical...
Baidu Health Partners with Shanghai Epiprobe for Cancer Early Screening
China Internet giant Baidu’s Health Internet Hospital unit has announced a partnership with Shanghai Epiprobe...
Pharmaniaga Partners with JD.com to Enter China Market
Malaysia-based pharma company Pharmaniaga Berhad (Pharmaniaga) is planning to bring its products into mainland China...
Eli Lilly’s Peresolimab and LOXO-783 Gain Tacit Clinical Trial Approvals in China
The Center for Drug Evaluation (CDE) in China has granted tacit clinical trial approvals to...
Hua Medicine Launches Dorzagliatin, a First-in-Class Diabetes Drug, in China
China-based Hua Medicine has announced the commercial launch of its Category 1 drug, dorzagliatin, with...